

CLAIMS

- 5 1. A gene delivery vehicle comprising a nucleic acid molecule
encoding apoptin-like activity.
- 5 2. A gene delivery vehicle according to claim 1 additionally
comprising a modified translation initiation site directly
upstream the ATG-initiation codon of said nucleic acid
molecule.
- 10 3. A gene delivery vehicle according to claim 2 wherein said
translation initiation site comprises the nucleic acid
sequence GCAAAC.
- 10 4. A gene delivery vehicle comprising a nucleic acid molecule
encoding VP2-like activity.
- 15 5. A gene delivery vehicle according to claim 4 additionally
comprising a modified translation initiation site directly
upstream the ATG-initiation codon of said nucleic acid
molecule.
- 15 6. A gene delivery vehicle according to any of claims 1 to 3
additionally comprising a nucleic acid molecule encoding VP2-
like activity.
- 20 7. A gene delivery vehicle according to claim 6 additionally
comprising a modified translation initiation site directly
upstream the ATG-initiation codon of the nucleic acid
molecule encoding VP2-like activity.
- 20 8. A gene delivery vehicle according to any of claims 1 to 7
which is a virus.
- 25 9. A gene delivery vehicle according to claim 8 which is a
replication-defective virus.
- 25 10. A gene delivery vehicle according to claim 8 or 9 which
is an adenovirus.
- 30 11. A gene delivery vehicle according to claim 8 or 9 which
is a retrovirus.
- 30 12. A gene delivery vehicle according to any of claims 1 to
11 which additionally comprises at least one target molecule

- sub 3
B*
- ~~13. A gene delivery vehicle according to claim 12 wherein the target molecule is reactive with a tumor cell surface receptor.~~
- sub 5
S*
- ~~14. A host cell comprising a gene delivery vehicle according to any of the claims 1-13.~~
- Sub 4
B*
- ~~15. A host cell according to claim 14 which is a helper or packaging cell.~~
- ~~16. A host cell according to claim 14 which is selected from the group of HEK;293, HER;911, PER.C6, Psi-2 and PA317 cells.~~
- 10a* ~~17. Use of a gene delivery vehicle according to any of claims 1-13 in cancer treatment.~~
- a* ~~18. Use of a gene delivery vehicle according to claim 17 in combination with conventional (chemo)therapy.~~
- a* ~~19. Use of a gene delivery vehicle according to any of claims 1-13 for the treatment of hyperplasia, metaplasia and dysplasia.~~
- a* ~~20. Use of a gene delivery vehicle according to any of claims 1-13 in diagnosis.~~
- 20* ~~21. Use of a gene delivery vehicle according to claim 20 in the in vitro detection of transformed, or cancerous, or hyperplastic, metaplastic or dysplastic cells.~~
- AAC
B5*

Add E4